AI in Pharmaceuticals

Main article: Artificial Intelligence in Medicine

2023

How AI and 3D printing revolutionise the creation of skincare products

Beauty brands combine AI and 3D printing technologies to create personalized skincare products that meet the needs of specific consumers. AI tools are rapidly gaining popularity in the beauty industry, according to a study released on November 15, 2023. Read more here.

Named the top 50 pharmaceutical companies leading in the development of artificial intelligence

Pharmaceutical companies around the world are massively introducing technologies, and artificial intelligence the leaders in this regard are, and Roche. Bayer Johnson & Johnson Such data are reflected in the CB Insights rating, which was published on August 8, 2023.

In total, 50 pharmaceutical companies from the USA and Europe are included in the published list. They are ranked according to the ability to attract talented specialists in the field of AI, implement projects in the relevant field, as well as introduce innovations through investments and research and development work. The rating is calculated based on CB Insights data, including patent applications, partner and license agreements, transaction and merger agreement activity, financial performance, bringing new products to market, etc.

Named the top 50 pharmaceutical companies leading in the development of artificial intelligence

Roche and Bayer are said to be the highest performing pharmaceutical companies primarily due to their leading level of innovation in AI, investment and patents in the field. In addition, they were among only three manufacturers from the rating who bought AI developer companies. The third such firm on the list is BioNTech.

Half of the 50 representatives of the rating entered into partnership or licensing agreements with AI technology companies. At the same time, 23 participants in the CB Insights list at least once in the last five years (by August 2023) mentioned AI in their financial results reports. At the same time, GSK mentioned AI in eight teleconferences on income statements - more than any other company. Some rating participants have formed AI destinations led by specialists with extensive academic or industry experience.^[1]

Postgres Professional will invest half a billion rubles in a drug development startup using AI

Russian developer DBMS Postgres Professional supported financial a company Ligand Pro that specializes in the development of drugs with use. artificial intelligence For the year, Ligand Pro received 100 million rubles investments from Postgres Professional. In the next three years, the company plans to invest at least half a billion rubles in the project. Postgres Professional representatives announced this Zdrav.Expert on August 10, 2023. More. here

2020: Bayer rolls out artificial intelligence to find new drugs to treat cancer and heart disease

In late January 2020, Bayer announced a collaboration with artificial intelligence drug discovery company Exscientia. As part of this partnership, the German giant is implementing partner solutions to investigate compounds that could potentially become drugs for the treatment of cardiovascular and oncological diseases. Read more here.

2018: Artificial intelligence will search for new antibiotics

Main article: Antibiotics

Resistance to antibiotics to is one of the big challenges of modern medicine. Thanks to the widespread use of antibiotics and non-compliance with doctor's instructions, drugs have ceased to affect bacteria, which causes problems in the treatment of both the most common everyday diseases and severe^[2] for^[3]

One technique that can cope with antibiotic resistance is the search for variants of known antibiotics. Unfortunately, this is an extremely difficult and time-consuming process. At least for people. When algorithms come into play, the question of time ceases to be so significant.

A group of Russian and American researchers has created an antibiotic algorithm that, quickly parsing databases, can open up 10 times more antibiotic options than has been discovered during the entire time of such studies in previous years.

The algorithm, known as VarQuest, is described in a paper published in the latest issue of Nature Microbiology. Hossein Mahimani, a professor at Carnegie Mellon University, tells^[4] in a news release that VarQuest completed a search that would have taken hundreds of years by traditional computing methods.

Mohimani also points out that VarQuest has managed to provide more than a thousand variants of peptide groups used to produce antibiotics in a record short time, and thus it can give microbiologists a broader perspective, perhaps even warn of trends or patterns of the microbiological world that would otherwise go completely unnoticed.

Notes